3 unknown. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Unknown 3 |
| Phase 2 | 1 | Unknown 1 |
Follow Refractory Multiple Myeloma: new trials by email Literature Review of Refractory Multiple Myeloma trials Research Report on Refractory Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma BCMA CAR-T cells - Multiple Myeloma, Relapse Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Shenzhen University General Hospital | 10 | 2021-07-01 | 2021-12-09 |
| Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. Selinexor, Lenalidomide, Methylprednisolone - Refractory Multiple Myeloma | Phase 1 | Unknown | Oncotherapeutics | 22 | 2020-11-01 | 2023-10-31 |
| Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients Bisthianostat - Refractory Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Unknown | Shanghai Theorion Pharmaceutical Co Ltd. | 30 | 2018-04-25 | 2019-09-19 |
Multiple Myeloma (3)
Blood Protein Disorders (3) · Cardiovascular Diseases (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Hemorrhagic Disorders (3) · Hemostatic Disorders (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Plasma Cell (3) · Paraproteinemias (3) · Vascular Diseases (3)
Lenalidomide (1) · Methylprednisolone (1) · selinexor (1)
Oncotherapeutics (1) · Shanghai Theorion Pharmaceutical Co Ltd. (1) · Shenzhen University General Hospital (1)
China (2) · United States (1)
James R Berenson, MD (1) · Jian Hou, MD (1) · Li Yu (1)